PNC-28

Targets cancer cells, induces apoptosis, is non-toxic to normal cells, and is a peptide-based therapy.

PNC-28

PNC-28

Targets cancer cells, induces apoptosis, is non-toxic to normal cells, and is a peptide-based therapy.

  • Starting at $499
Order PNC-28

What Is PNC-28?

PNC-28 is an investigational peptide derived from a segment of the p53 tumor suppressor protein. It has been studied in preclinical research for its ability to selectively target cancer cells by binding to HDM-2 (also known as MDM2), a protein involved in regulating p53 activity. In laboratory settings, PNC-28 has demonstrated the ability to induce cancer cell membrane disruption while showing minimal effects on healthy cells. Its mechanism is distinct from traditional chemotherapy or hormone-based approaches.

  • Derived from the p53 tumor suppressor domain.
  • Studied for selective targeting of malignant cells.
  • Investigated for membrane-based cytotoxic activity.

Who Is PNC-28 Intended For?

PNC-28 is considered an investigational compound and is not FDA-approved for the treatment of cancer or any medical condition. It may be explored strictly within physician-guided research or investigational frameworks.

  • PNC-28 is not approved by the FDA for the diagnosis, treatment, mitigation, or prevention of any disease.
  • It is considered investigational and should not replace evidence-based oncology care.
  • Individuals with active malignancy should remain under the care of a licensed oncologist.

OUR CLIENTS LOVE US - SEE WHAT THEY'RE SAYING

Frequently Asked Questions –
Your Concierge Healthcare, Simplified

No. PNC-28 is not chemotherapy. It works through a different proposed mechanism involving membrane disruption in malignant cells.

No. It is investigational and not approved for cancer therapy.

No. It should never replace conventional oncology care. Any investigational use must be discussed with an oncology specialist.